Nutrition and polymers were the stand-out divisions for Royal DSM in 2011, a year that saw operating profits rise 15% from €752m to €866m, as the newly life science-oriented ingredients giant singled out Martek buy-out success and committed to ongoing...
Martek’s new algal EPA/DHA blend - the ‘fishless fish oil’ - is gaining momentum in the market with recent launches including Schiff’s MegaRed Plant-Omega supplements and Darigold Omega-3 2% milk.
Martek “clearly exceeded expectations” in the third quarter for new owner DSM within a nutrition division that continued to deliver “robust” results despite the negative impact of currency translation.
Seven months after sealing a billion dollar deal to acquire Martek, DSM has created Nutritional Lipids, a new division that will combine Martek’s algal omega-3 and omega-6 products and DSM Nutritional Products’ polyunsaturated fatty acid (PUFA) portfolio.
Algae Biosciences Corporation – a high-profile new entrant to the omega-3 fatty acid market – has unveiled detailed figures on anticipated production volumes after finalizing a deal to build the first phase of its new production facility near Holbrook...
Royal DSM’s acquisition of Martek Biosciences Corporation has moved a step closer to finalisation with the news that its tender offer to buy all of the company’s outstanding shares of common stock at a price of $31.50 (about €24) per share has proved...
Greenback Acquisition Corporation, a wholly-owned Royal DSM subsidiary, has begun the formal tender for Martek Biosciences, which DSM announced it was buying for €829m ($1.087bn) last month.
Royal DSM will drive Martek’s predominantly US-based, omega-3 DHA infant nutrition business to new shores, and fast-track its food and beverage ambitions, after having its billion-dollar bid accepted by the Maryland company’s Board.
Increased sales of nutritional ingredients in both the infant formula and non-infant formula markets plus the acquisition of health and wellness company Amerifit helped Martek Biosciences achieve a 30 per cent increase in 2010 revenues to reach $450m.
Martek Bioscience has said it is expanding its omega-3 range by commercializing two new products – a new emulsion version of its vegetarian life’s DHA and a DHA/EPA blend from algal sources.
DHA omega-3 is one of the few ingredients to benefit from the European Union nutrition and health claims process so far, and Martek's VP of regulatory affairs, Rodney Gray, looks at developments in other regulatory changes that have affected the...
Capsugel France has agreed to purchase all its algal DHA omega-3 exclusively from Martek Bioscience Corporation in the second patent dispute Martek has settled in a week.
Global DHA leader, Martek Biosciences, has gained a draft European Union Novel Foods approval for its proprietary omega-3 ingredient, life'sDHA, to be used in a host of food and beverage applications.
Martek Biosciences Corporation is disappointed but not devastated by the European Food Safety Authority’s rejection of its article 14 DHA/ARA infant nutrition health claim.
Martek BioSciences has launched a new protein-free version of its
flagship DHA ingredient, which the firm is positioning for use in
foods and supplements that contain no allergens.
Martek Biosciences is extending its options in the competitive
plant-derived omega-3 market, amending its agreement with SemBioSys
from safflower to a traditional commodity crop as well.
Martek Biosciences Corporation has announced plans to restructure
its plant operations, including the layoff of 15 percent of its
workforce, following a review of the company's current production
and cost structure.
Martek Biosciences has entered into a 15-year supply agreement,
that includes co-branding priviledges, with WhiteWave Foods for the
development of soy beverages containing Martek's flagship omega-3
ingredient, life'sDHA.
Martek Biosciences' operating profit leaped back into the black in
Q3, as it continues to reap rewards from the fortified infant
formula boom and more cost-effective DHA production.
Increased international sales from a thriving infant formula market
drove up Martek's net income by almost 85 percent in Q2, and new
deals point to positive results for the remainder of the year.
With its new supply agreement with Mead Johnson Nutritionals,
Martek Biosciences solidifies its position in the world market for
DHA and ARA, as alternative omega-3 sources are approved for infant
formula use.
A Maryland court has ruled in favor of Martek Biosciences in a
motion of summary judgment of an outstanding dispute with the
former interest holders of OmegaTech, the DHA producer it acquired
in March 2002.
Martek Biosciences has released its third quarter financial
results, with a steep 17 percent drop in sales. But although
operating income also took a dive, the poor quarter is not a sign
of waning interest in nutritional oils. Rather,...
The stockpiles of Martek products being held by the firm's
customers caused a slowdown in revenue growth for the second
quarter but it claims that extra capacity coming on stream this
year will see a new surge in demand, reports...
Shareholders who have become aware of an omega-6 mountain in the
stockrooms of Martek customers have filed a lawsuit seeking class
action status against the company, alleging that it flooded
customers with inventory in order to meet...
After a successful third quarter, Martek Biosciences will be hoping
that the Food and Drug Administration's (FDA) announcement last
week that conventional foods will now be able to display a
qualified health claim for omega-3...
Fatty acids producer Martek Biosciences continued its recent
profit-making run during the second quarter, which should help its
plans to expand further into new markets and new applications,
writes Philippa Nuttall.
Maryland-based Martek Biosciences is facing further tightening of
ARA supply, after a fire shut down production of the fatty acid by
key supplier DSM last weekend.
DSM Food Specialties is to double the volume of arachidonic acid
(ARA) produced for its US partner Martek Biosciences to meet
rapidly growing demand, the Dutch firm said this week, writes
Dominique Patton.
License agreements with leading infant formula makers helped Martek
Biosciences maintain a strong revenue stream in this year's first
quarter but although it has continued last year's profit-making run
through to 2004, margins...
Martek Biosciences said yesterday that the Food and Drug
Administration (FDA) has completed a favorable review of its safety
data on the former Omega Tech DHA product, currently being marketed
by the company for use in food applications.
US fatty acids manufacturer Martek Biosciences is to distribute its
docosahexaenoic acid (DHA) to European dietary supplement makers
through an agreement with Dutch firm Vegetable Seed Oil Products
(VSP).
The infant formula oils made by US-based Martek Biosciences, could
soon be used by formula manufacturers in Canada, after being
reviewed and passed by Canada's government health agency.
Martek Biosciences, the US group which specialises in omega-3 oils,
has reported net losses of $3.7 million (€3.8m) for the third
quarter of the current year, but said that its restructuring
efforts were beginning to bear fruit.
Martek Biosciences has completed its acquisition of OmegaTech, the
producer of DHA fatty acids from algae, following a share-only deal
which saw OmegaTech become a fully-owned subsidiary of Martek.
Martek Biosciences Corporation is to buy docosahexaenoic acid (DHA)
producer OmegaTech, giving it a further foothold in the growing
market for fortified foods. Martek said it would become the world
leader in fermentation-derived DHA...
US company Martek Biosciences Corporation that develops,
manufactures and sells products from microalgae for nutritional
foods, announced recently that it has sold the assets of its stable
isotope business unit to Spectra Gases, Inc.,...
